Physician profile
Veronica Perez
NPI 1013552397
$2,276.94
in general payments reported to CMS, 2019-2025
15 companies · $575 in 2025
The $575 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $366 · 2023: $316 · 2024: $615 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,506.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $641.51 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.25 | 2022-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $303.02 | 2021-2022 | |
| Lilly USA, LLC | $288.56 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $150.33 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $143.69 | 2024-2025 | Breztri |
| Abiomed | $142.76 | 2024 | Impella |
| Abbvie INC. | $72.26 | 2024 | |
| Ardelyx, INC. | $64.53 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $36.06 | 2024 | |
| Procept Biorobotics Corporation | $32.19 | 2025 | |
| Dexcom, INC. | $20.16 | 2024 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $19.74 | 2023 | Quviviq |
| Amgen INC. | $16.82 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.06 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.